CSL - Ebitda

Stock Price
141.02
Daily Change
0.36 0.26%
Monthly
-7.67%
Yearly
-43.07%
Q1 Forecast
138.07

CSL reported $3.13B in EBITDA for its fiscal semester ending in December of 2025.





Ebitda Change Date
Alterity Therapeutics Limited AUD -7.72M 2.99M Jun/2023
Arca Biopharma USD -25.07M 5.23M Mar/2025
aTyr Pharma USD -26.58M 26.32M Sep/2025
Bio Path USD -3.21M 631K Mar/2025
Brainstorm Cell Therapeutics USD -3.04M 99K Mar/2025
Cara Therapeutics USD -2.39M 3.16M Mar/2025
CSL USD 3.13B 1.17B Dec/2025
Curis USD -12.3M 231K Sep/2023
Esperion Therapeutics USD -9.93M 24.99M Sep/2025
Immunic USD -22.78M 753K Jun/2024
Infinity Pharmaceuticals USD -10.01M 1.39M Jun/2023
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
TherapeuticsMD USD -1.64M 700K Sep/2023